Lido Advisors LLC Invests $364,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Lido Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 27,487 shares of the company's stock, valued at approximately $364,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TAK. Summit Global Investments boosted its stake in shares of Takeda Pharmaceutical by 75.5% during the 4th quarter. Summit Global Investments now owns 729,200 shares of the company's stock worth $9,655,000 after purchasing an additional 313,642 shares during the period. Northern Trust Corp boosted its position in shares of Takeda Pharmaceutical by 14.6% during the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after buying an additional 238,161 shares during the period. Crossmark Global Holdings Inc. grew its stake in shares of Takeda Pharmaceutical by 284.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company's stock valued at $2,787,000 after buying an additional 155,795 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Takeda Pharmaceutical in the fourth quarter worth approximately $1,447,000. Finally, Marshall Wace LLP purchased a new position in Takeda Pharmaceutical during the 4th quarter valued at $1,010,000. Institutional investors own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Trading Up 0.6 %

TAK stock traded up $0.09 during mid-day trading on Friday, reaching $14.36. The company had a trading volume of 4,353,385 shares, compared to its average volume of 1,893,701. The company has a market capitalization of $45.69 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The firm has a 50 day moving average of $14.88 and a 200 day moving average of $13.99. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.43. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The firm had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.